PROGRESSIVE MS - MORE THAN A MILLION PEOPLE NEED ANSWERS

Progressive multiple sclerosis (MS) is a chronic condition that disrupts the flow of information within the brain and body, and gets worse over time. Progressive MS takes things away from people: vision, mobility, cognition, ability to work, and their independence. More than 2.3 million people worldwide currently live with MS; over 1 million people live with a progressive form of the disease.

DONATE TODAY - WE CAN CHANGE THE LIVES OF MILLIONS

People with progressive MS cannot wait any longer. The Alliance relies on the support of generous donors from around the world. With the participation of each person, organization and partner, we become stronger and more powerful than progressive MS. Join us and help change the world. Together we will end this disease.

CONTACT US TODAY
www.ProgressiveMSAlliance.org
info@progressivemsalliance.org

“One of the hardest parts of MS is that no one can show you a chart and say ‘you are here, and in ten years you’ll be there’.”
Gary, living with MS since 2000, Australia

“My future with MS is so uncertain. I could give up… and that’s why I need people around me to keep the momentum going.”
Mary, living with MS since 2006, United Kingdom

INTERNATIONAL PROGRESSIVE MS ALLIANCE
CONNECT TO END PROGRESSIVE MS

CHANGING THE LIVES OF MILLIONS

GARY
LIVING WITH MS SINCE 2000, AUSTRALIA

ROBERTA
LIVING WITH MS SINCE 1992, ITALY

“Another part of MS is being with your family, having people around you who care. I feel very lucky.”
Roberta, living with MS since 1992, Italy

“MS is a disease that test your will and your strength.”
Gary, living with MS since 2000, Australia
BARRIERS TO DEVELOPING SOLUTIONS

Despite advances in managing other forms of MS, progressive MS remains hard to understand and treat. Progressive MS does not have a single, identifiable disease pattern, so the experience of living with it is different for each person.

As a result, researchers lack the knowledge needed to focus and accelerate progress, and clinicians are challenged to identify effective treatments.

Without a clear understanding and an accelerated path to new treatments, people with progressive MS live with the possibility of losing ground each day.

“BARRIERS TO DEVELOPING SOLUTIONS”

AN UNPRECEDENTED GLOBAL EFFORT

For the first time, the international MS community is coming together to tackle progressive MS. The Progressive MS Alliance is a global initiative that aligns MS organizations from around the world including Australia, Belgium, Canada, Denmark, Germany, Italy, the Netherlands, Spain, the United Kingdom, the United States and the MS International Federation.

MANAGING MEMBERS:

INTERNATIONAL COLLABORATION WILL FIND ANSWERS

Global collaboration is the best way to find solutions for progressive MS. The Progressive MS Alliance is uniquely positioned to make this happen by driving worldwide resources to fund the best research with the most impact and potential, wherever it may be.

The Alliance has four research priorities that will transform the landscape:

• Better understand progression so treatments can be identified and tested.
• Design shorter, faster trials that measure patient outcomes.
• Conduct trials to test agents. With better trial design, more life changing treatment choices will be available to people faster.
• Develop and evaluate effective rehabilitation and symptomatic treatments that will improve daily quality of life.

FUELING NECESSARY RESEARCH TO SPEED UP TREATMENT DEVELOPMENT

Two pioneering research programs are being funded through the Alliance:

CHALLENGE AWARDS:

Innovative research to improve understanding of genetic and biologic processes involved in progressive MS, improving clinical trials, and re-purposing existing drugs.

COLLABORATIVE AWARDS:

Long-term, multi-national projects stimulating research into the biggest questions facing MS scientists, like speeding up new treatments and the development of new trials.

JASON
LIVING WITH MS SINCE 2005, UNITED STATES

LOUISE
LIVING WITH MS SINCE 1997, DENMARK

“The Alliance is bringing the world together so that we can solve progressive MS and treat it.”
Professor Alan Thompson
Dean, UCL Faculty of Brain Sciences
University College London

“Our purpose is clear - to speed up the development of treatments for people with progressive MS.”
Professor Giancarlo Comi
Director, Dept. of Neurology
Scientific Institute San Raffaele, Italy

“Better understand progression so treatments can be identified and tested.”
Amit Bar-Or, MD
Associate Professor, Neurology and Neurosurgery
Montreal Neurological Institute
McGill University, Canada

“Managing members:”

MEMBERS:

“International collaboration will find answers”

“Rapidly improving quality of life.”
Jason, living with MS since 2005, United States

“Fueling necessary research to speed up treatment development”

“Challenge awards:”

Innovative research to improve understanding of genetic and biologic processes involved in progressive MS, improving clinical trials, and re-purposing existing drugs.

“Collaborative awards:”

Long-term, multi-national projects stimulating research into the biggest questions facing MS scientists, like speeding up new treatments and the development of new trials.

“‘The biggest challenge in finding treatments in progressive MS is the lack of understanding of what causes progression.”
Amit Bar-Or, MD
Associate Professor, Neurology and Neurosurgery
Montreal Neurological Institute
McGill University, Canada

“The Alliance is bringing the world together so that we can solve progressive MS and treat it.”
Professor Alan Thompson
Dean, UCL Faculty of Brain Sciences
University College London

“Our purpose is clear - to speed up the development of treatments for people with progressive MS.”
Professor Giancarlo Comi
Director, Dept. of Neurology
Scientific Institute San Raffaele, Italy

“Managing members:”

MEMBERS:

“International collaboration will find answers”

“Rapidly improving quality of life.”
Jason, living with MS since 2005, United States

“Fueling necessary research to speed up treatment development”

“Challenge awards:”

Innovative research to improve understanding of genetic and biologic processes involved in progressive MS, improving clinical trials, and re-purposing existing drugs.

“Collaborative awards:”

Long-term, multi-national projects stimulating research into the biggest questions facing MS scientists, like speeding up new treatments and the development of new trials.

“‘The biggest challenge in finding treatments in progressive MS is the lack of understanding of what causes progression.”
Amit Bar-Or, MD
Associate Professor, Neurology and Neurosurgery
Montreal Neurological Institute
McGill University, Canada

“International collaboration will find answers”

“Rapidly improving quality of life.”
Jason, living with MS since 2005, United States

“Fueling necessary research to speed up treatment development”

“Challenge awards:”

Innovative research to improve understanding of genetic and biologic processes involved in progressive MS, improving clinical trials, and re-purposing existing drugs.

“Collaborative awards:”

Long-term, multi-national projects stimulating research into the biggest questions facing MS scientists, like speeding up new treatments and the development of new trials.

“‘The biggest challenge in finding treatments in progressive MS is the lack of understanding of what causes progression.”
Amit Bar-Or, MD
Associate Professor, Neurology and Neurosurgery
Montreal Neurological Institute
McGill University, Canada

“International collaboration will find answers”

“Rapidly improving quality of life.”
Jason, living with MS since 2005, United States

“Fueling necessary research to speed up treatment development”

“Challenge awards:”

Innovative research to improve understanding of genetic and biologic processes involved in progressive MS, improving clinical trials, and re-purposing existing drugs.

“Collaborative awards:”

Long-term, multi-national projects stimulating research into the biggest questions facing MS scientists, like speeding up new treatments and the development of new trials.

“‘The biggest challenge in finding treatments in progressive MS is the lack of understanding of what causes progression.”
Amit Bar-Or, MD
Associate Professor, Neurology and Neurosurgery
Montreal Neurological Institute
McGill University, Canada